Compare DBL & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBL | CDXS |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Major Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.5M | 256.3M |
| IPO Year | N/A | 2008 |
| Metric | DBL | CDXS |
|---|---|---|
| Price | $14.44 | $2.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.5K | ★ 756.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $14.08 | $0.96 |
| 52 Week High | $16.01 | $3.87 |
| Indicator | DBL | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 44.97 |
| Support Level | $14.13 | $2.39 |
| Resistance Level | $14.59 | $2.56 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 64.80 | 16.52 |
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.